Basit öğe kaydını göster

dc.contributor.authorMalpas, C.
dc.contributor.authorSharmin, S.
dc.contributor.authorHorakova, D.
dc.contributor.authorHavrdova, E. K.
dc.contributor.authorTrojano, M.
dc.contributor.authorIzquierdo, G.
dc.contributor.authorSpitaleri, D.
dc.date.accessioned2020-06-21T13:06:38Z
dc.date.available2020-06-21T13:06:38Z
dc.date.issued2018
dc.identifier.issn1352-4585
dc.identifier.issn1477-0970
dc.identifier.urihttps://hdl.handle.net/20.500.12712/11391
dc.description34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) -- OCT 10-12, 2018 -- Berlin, GERMANYen_US
dc.descriptionAltintas, Ayse/0000-0002-8524-5087; McCombe, Pamela/0000-0003-2704-8517; Turkoglu, Recai/0000-0001-9724-851X; Lugaresi, Alessandra/0000-0003-2902-5589;en_US
dc.descriptionWOS: 000446861401329en_US
dc.description.abstracten_US
dc.description.sponsorshipEuropean Comm Treatment & Res Multiple Sclerosisen_US
dc.description.sponsorshipBiogenBiogen; Charles University in Prague [PRVOUK-P26/LF1/4]; Czech Minsitry of Education [Q27/LF1]; Czech Ministry of HealthMinistry of Health, Czech Republic [NT13237-4/2012]; Biogen-IdecBiogen; MerckMerck & Company; NovartisNovartis; Bayer ScheringBayer AG; Sanofi-AventisSanofi-Aventis; Teva; Biogen IdecBiogen; Sanofi Genzyme; BayerBayer AG; SanofiSanofi-Aventis; Sanofi-Genzyme; RocheRoche Holding; Fondazione Italiana Sclerosi Multipla (FISM)Fondazione Italiana Sclerosi Multipla (FISM); Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); CIHRCanadian Institutes of Health Research (CIHR); MS Society of Canada; GenzymeGenzyme Corporation; Teva-Neuroscience; Teva Neurosciences; Mitsubishi; ONO Pharmaceuticals; Novartis Pharma; Almirall; Associazione Marchigiana Sclerosi Multipla e altre malattie neurologiche; Sanofi AventisSanofi-Aventis; Bayer-ScheringBayer AG; Biogen - Gen Pharmaen_US
dc.description.sponsorshipDana Horakova received speaker honoraria and consulting fees from Biogen, Merck, Teva and Novartis, as well as support for research activities from Biogen and research grants from Charles University in Prague [PRVOUK-P26/LF1/4], Czech Minsitry of Education [PROGRES Q27/LF1] and Czech Ministry of Health [NT13237-4/2012].; Maria Trojano received speaker honoraria from Biogen-Idec, Bayer-Schering, Sanofi Aventis, Merck, Teva, Novartis and Almirall; has received research grants for her Institution from Biogen-Idec, Merck, and Novartis.; Roberto Bergamaschi received speaker honoraria from Bayer Schering, Biogen, Genzyme, Merck, Novartis, Sanofi-Aventis, Teva; research grants from Bayer Schering, Biogen, Merck, Novartis, Sanofi-Aventis, Teva; congress and travel/accommodation expense compensations by Almirall, Bayer Schering, Biogen, Genzyme, Merck, Novartis, Sanofi-Aventis, Teva.; Patrizia Sola served on scientific advisory boards for Biogen Idec and TEVA, she has received funding for travel and speaker honoraria from Biogen Idec, Merck, Teva, Sanofi Genzyme, Novartis and Bayer and research grants for her Institution from Bayer, Biogen, Merck, Novartis, Sanofi, Teva.; Diana Ferraro received travel grants and/or speaker honoraria from Merck, TEVA,dagger Novartis, Biogen and Sanofi-Genzyme.; Alessandra Lugaresi is a Bayer, Biogen, Genzyme, Merck Advisory Board Member. She received travel grants and honoraria from Roche, Bayer, Biogen, Merck, Novartis, Sanofi, Teva and Fondazione Italiana Sclerosi Multipla (FISM). Her institution received research grants from Bayer, Biogen, Merck, Novartis, Sanofi, Teva and Fondazione Italiana Sclerosi Multipla (FISM).; Marc Girard received consulting fees from Teva Canada Innovation, Biogen, Novartis and Genzyme Sanofi; lecture payments from Teva Canada Innovation, Novartis and EMD.dagger He has also received a research grant from Canadian Institutes of Health Research.; Pierre Duquette served on editorial boards and has been supported to attend meetings by EMD, Biogen, Novartis, Genzyme, and TEVA Neuroscience. He holds grants from the CIHR and the MS Society of Canada and has received funding for investigator-initiated trials from Biogen, Novartis, and Genzyme.; Pierre Grammond is a Merck, Novartis, Teva-neuroscience, Biogen and Genzyme advisory board member, consultant for Merck, received payments for lectures by Merck, Teva-Neuroscience and Canadian Multiple sclerosis society, and received grants for travel from Teva-Neuroscience and Novartis.; Francois Grand'Maison received honoraria or research funding from Biogen, Genzyme, Novartis, Teva Neurosciences, Mitsubishi and ONO Pharmaceuticals.; Vincent Van Pesch received travel grants from Biogen, Bayer Schering, Genzyme, Merck, Teva and Novartis Pharma. His institution receives honoraria for consultancy and lectures from Biogen, Bayer Schering, Genzyme, Merck, Roche, Teva and Novartis Pharma as well as research grants from Novartis Pharma and Bayer Schering.; Franco Granella received research grant from Biogen, served on scientific advisory boards for Biogen, Novartis, Merck, and Sanofi-Aventis and received funding for travel and speaker honoraria from Biogen, Merck, Sanofi-Aventis, and Almirall.; Eugenio Pucci served on scientific advisory boards for Merck, Genzyme and Biogen; he has received honoraria and travel grants from Sanofi Aventis, Novartis, Biogen, Merck, Genzyme and Teva; he has received travel grants and equipment from "Associazione Marchigiana Sclerosi Multipla e altre malattie neurologiche".; Gerardo Iuliano had travel/accommodations/ meeting expenses funded by Bayer Schering, Biogen, Merck, Novartis, Sanofi Aventis, and Teva.; Murat Terzi received travel grants from Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis.; Ayse Altintas received personal fees and speaker honoraria from Teva, Merck, Biogen - Gen Pharma, Roche, Novartis, Bayer, Sanofi-Genzyme; received travel and registration grants from Merck, Biogen - Gen Pharma, Roche, Sanofi-Genzyme and Bayer.en_US
dc.language.isoengen_US
dc.publisherSage Publications Ltden_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleEarly clinical predictors of severe MSen_US
dc.typeconferenceObjecten_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume24en_US
dc.identifier.startpage538en_US
dc.identifier.endpage540en_US
dc.relation.journalMultiple Sclerosis Journalen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster